Showing 31-40 of 1017 results for "".
How New Molluscum Contagiosum Treatments Will Boost QoL and Limit Infection
https://practicaldermatology.com/topics/pediatric/how-new-molluscum-contagiosum-treatments-will-boost-qol-and-limit-infection/20244/Adam Friedman, MD, George Washington School of Medicine discusses the first FDA-approved nitric-oxide based drug in dermatology plus other recent approvals that he believes will make patients lives much easier and reduce the continuity of this condition.COVID-19 Coping Strategies
https://practicaldermatology.com/topics/practice-management/covid-19-coping-strategies/19755/Nina Chaifetz, LCSW-R, a licensed clinical social worker and co-founder of Lotus Psychotherapy in New York, offers strategies to use every day to lessen anxiety, especially now as the COVID-19 pandemic continues to disrupt our world and increases feelings of fear, stress, and uncertainty.Targeting Tech Neck
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/targeting-tech-neck/19617/Today’s tech-obsessed population is always looking down at devices, creating lines and wrinkles in the neck. Kim Nichols, MD describes the problem of Tech Neck and the regimen she uses to treat it.Social Media Pearls and Pitfalls
https://practicaldermatology.com/topics/practice-management/social-media-pearls-and-pitfalls/18917/Despite offering new opportunities to reach patients, social media platforms also introduce a number of potential pitfalls for physicians. In this edition of Derm Insider, host Neal Bhatia discusses the complex spectrum of social media with guests Abel Torres, MD, Mark Kaufmann, MD, and Nicole DeyamDermatologists Push Back on Wall Street Journal Characterization
https://practicaldermatology.com/issues/january-february-2025/dermatologists-push-back-on-wsj-characterization/32900/Four-day workweeks, double the salary of some colleagues and no emails at night—those were the reasons a Wall Street Journal article concluded that medical residency applications for dermatology slots are up 50% over the past 5 years. Practical Dermatology reached out to dermatologists to get theirEyes Have It: Bloodless Blephs and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/eyes-have-it-bloodless-blephs-and-more/18728/Demand for treatments around the eye continue to grow; patients want big results but little downtime. Dr. Niamtu discusses his "bloodless bleph" and other uses for fillers and toxins.DermWireTV: Allē Launches; Arazlo Cleared; BTL Files Suit
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-alle-launches-arazlo-cleared-btl-files-suit/19714/More than 10 Years and 6 million members later, the Brilliant Distinctions program is being relaunched with a new name and a new app: Allē. Arazlo Lotion 0.045%, the first lotion formulation of tazarotene, is now FDA approved for the topical treatment of acne vulgaris in patients nine years of age aEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andThe Invasion of the Picoseconds
https://practicaldermatology.com/topics/practice-management/the-invasion-of-the-picoseconds/20763/Pico devices are finding their niche, with expanded applications that may make them more attractive for practices.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at Take